It is estimated, that globally more than 300 million people suffer from depression. Latest research has shown that the pandemic might has added another 50 million on top of that. Sadly, 1 in 3 patients do not benefit from current available treatments and develop treatment resistant depression over time.
Unfortunately, there are not a lot of options left for those patients. While there have been more than 80 drugs approved in oncology since 2015 it was only 7 in mental health.
The Kieger Impact Healthcare Fund has a strong focus on mental health and also investing in new and more holistic psychedelic therapies.
The field of psychedelic drugs has been re-emerging quite a lot over the last years with very good and promising clinical data and also FDA breakthrough designations for example for a psylocibin therapy. Psylocibin is the active psychedelic substance in more than 200 fungi worldwide.
Hopefully, these new and more holistic therapies will soon help millions of people around the globe to get back to their families and friends, to get back to work and also to get back to joy in their lifes.
Link to our funds: https://kieger.com/ucits/
We attended the ASCO 2023 annual meeting in Chicago. After the rise of immuno-oncology, COVID-19 challenged clinical trial execution and muted patient numbers. In the last years we saw many setbacks of once promising immuno-oncology combinations trials.
What mattered this month in healthcare? Q1 reporting came to a close, and FTC action put pressure on the biopharma space and... Find out more in our monthly healthcare newsletter.
With M&A picking up, are we at a turning point for biotech? Check out our latest Kieger AG Chart of the Month Video.